Derma Sciences Completes Equity and Debt Financings

The net proceeds of the transaction will be used to finance the Company’s growth plans, which include acquisitions, ongoing research and development as well as working capital for general corporate purposes. Speaking of the financing, Derma Sciences CEO Edward J. Quilty said, “We’re pleased to have obtained additional capital to further our strategic growth plan through the advancement of differentiated internal programs and the acquisition of synergistic businesses. The additional capital will help finance the recent acquisitions of the first aid division of NutraMax and the Angiotensin Analog technology license from USC. These transactions significantly expand our private label capabilities and position us to capitalize on a potentially major pharmaceutical treatment for wounds and scars.”

About Derma Sciences:

Derma Sciences is a manufacturer and marketer of advanced wound care products, with operations based in the US and Canada, and sales worldwide. The company sources Active Manuka (Leptospermum scoparium) Honey from Comvita New Zealand, Ltd. Comvita controls over 70% of the flow of manuka honey, and owns several patents around the use of honey in wound dressings. The Company has also obtained FDA clearance to market and sell its MOBILITY-1? boot and compressor device for the treatment of venous ulcers, lymphedema, and other conditions that require compression therapy. For more information about Derma Sciences, Inc., visit its home page on the Internet at .

Forward-looking Statements

Statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned, that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company’s results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements Include but are not limited to, those discussed in the Company’s filings with the Securities and Exchange Commission.